EUVIMEDEUVIMED entdecken
Systematische Übersicht

Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®

Debanjali Purkayastha, Kyla Agtarap, Kristy Wong, Onella Pereira, Jannie Co, Smita Pakhale, Salmaan Kanji

Journal of Cystic Fibrosis · 2023

DOI: 10.1016/j.jcf.2023.01.005 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Cystic Fibrosis, 2023. Verfasst von Debanjali Purkayastha und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Waterloo, Kitchener, ON, Canada. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of CFTR modulators ivacaftor, tezacaftor and elexacaftor (Trikafta®, Kaftrio®) significantly improve outcomes, including survival in a broad range of cystic fibrosis patients. These drugs have complicated metabolic profiles that make the potential for drug interactions an important consideration for prescribers, care providers and patients. Prolonged survival also increases risk of age-related disease and their associated pharmacotherapy, further increasing the risk of drug interactions and the need for increased vigilance amongst care providers. We systematically searched the literature for studies identifying and evaluating pharmacokinetic and pharmacodynamic drug interactions involving the components of Trikafta®/Kaftrio®. We also searched electronic databases of drugs for possible drug interactions based on metabolic profiles. We identified 86 potential drug interactions of which 13 were supported by 14 studies. There is a significant need for research to describe the likelihood, magnitude and clinical impact of the drug interactions proposed here.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansCystic Fibrosis Transmembrane Conductance RegulatorMutationAminophenolsBenzodioxolesDrug CombinationsDrug InteractionsIndolesPyrazolesPyridinesQuinolines

Stichwörter der Autor:innen

CFTR modulatorCystic fibrosisDrug interactionsElexacaftorIvacaftorPharmacokineticsTezacaftor

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorAminophenolsBenzodioxolesDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationIndolesPyrazolesPyridinesQuinolinesCFTR protein, human

Autor:innen und Institutionen

  • University of Waterloo, Kitchener, ON, Canada.
  • St. Michael's Hospital, Toronto, ON, Canada.
  • The Ottawa Hospital, Ottawa, ON, Canada.
  • Department of Medicine, The Ottawa Hospital, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
  • Department of Pharmacy, The Ottawa Hospital, Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada. Electronic address: skanji@toh.ca.

Zitieren

APA

Purkayastha, D., Agtarap, K., Wong, K., Pereira, O., Co, J., Pakhale, S., & Kanji, S. (2023). Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2023.01.005

Vancouver

Purkayastha D, Agtarap K, Wong K, Pereira O, Co J, Pakhale S, et al. Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®. Journal of Cystic Fibrosis. 2023. doi:10.1016/j.jcf.2023.01.005

BibTeX
@article{Purkayastha2023,
  author = {Purkayastha, Debanjali and Agtarap, Kyla and Wong, Kristy and Pereira, Onella and Co, Jannie and Pakhale, Smita and Kanji, Salmaan},
  title = {Drug-drug interactions with CFTR modulator therapy in cystic fibrosis: Focus on Trikafta®/Kaftrio®},
  journal = {Journal of Cystic Fibrosis},
  year = {2023},
  doi = {10.1016/j.jcf.2023.01.005}
}
Kostenlos starten →